5-MeO-pyr-T (5-methoxy-N,N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It is the 5-methoxyanalog of pyr-T. 5-MeO-pyr-T was first synthesized by Hunt & Brimblecombe,[1] who credited S. Mitzal for characterization of chemical properties.[2] Later human tests were reported by Alexander Shulgin, in his book TiHKAL. An oral dosage of 0.5 to 2 mg, and an inhaled dosage of 2–3 mg are reported. 5-MeO-pyr-T causes varying reactions, such as amnesia, tinnitus, vomiting, and a 5-MeO-DMT-like rushing sensation. At the highest dosage reported in TiHKAL, the subject describes awakening from an apparent fugue state during which they were wandering the streets, with complete amnesia upon awakening.[3]
Testing was performed on rats using this compound while characterizing various agonists of the 5-HT7 receptor. It is an agonist with a Ki value of 630.96nM.[4]
Very little other data exists about the pharmacological properties, metabolism, and toxicity of 5-MeO-pyr-T.
^Hunt, R. R.; Brimblecombe, R. W. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry. 10 (4): 646–648. doi:10.1021/jm00316a027. PMID4962512.
^Mitzal, S. (1962). "N/A". Dissertationes Pharm. 14: 305.
^Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL, The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 548–551. ISBN0-9630096-9-9. Retrieved 7 April 2018.
^Vermeulen, Erik S.; Schmidt, Anne W.; Sprouse, Jeffrey S.; Wikström, Håkan V.; Grol, Cor J. (2003). "Characterization of the 5-HT7 Receptor. Determination of the Pharmacophore for 5-HT7 Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site". Journal of Medicinal Chemistry. 46 (25): 5365–5374. doi:10.1021/jm030826m. PMID14640545.
